	US 12,285,488 B2
	Oral dosage form containing theobromine-free cocoa
Thomas Hille, Neuwied (DE); Gabriel Wauer, Ahrweiler (DE); and Frank Seibertz, Bad Breisig (DE)
Assigned to LTS Lohmann Therapie-Systeme AG, Andernach (DE)
Appl. No. 16/977,018
Filed by LTS LOHMANN THERAPIE-SYSTEME AG, Andernach (DE)
PCT Filed Mar. 1, 2018, PCT No. PCT/EP2018/055105 § 371(c)(1), (2) Date Aug. 31, 2020, PCT Pub. No. WO2019/166098, PCT Pub. Date Sep. 6, 2019.
Prior Publication US 2021/0000963 A1, Jan. 7, 2021
Int. Cl. A61K 47/46 (2006.01); A61K 9/00 (2006.01); A61K 31/4178 (2006.01); A61K 31/4196 (2006.01); A61K 31/465 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/18 (2017.01); A61K 47/26 (2006.01); A61K 47/32 (2006.01); A61K 47/38 (2006.01)

CPC A61K 47/46 (2013.01) [A61K 9/0053 (2013.01); A61K 31/4178 (2013.01); A61K 31/4196 (2013.01); A61K 31/465 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/186 (2013.01); A61K 47/26 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01)]

14 Claims

1. An oral dosage form in the form of an oral film which, when administered, releases an active pharmaceutical ingredient into the oral and pharyngeal cavity, said oral dosage form containing:

a) at least one active pharmaceutical ingredient;

b) at least one excipient; and

c) theobromine-free cocoa, wherein the oral dosage form contains at most 10% by weight of theobromine-free cocoa.